Worst of both worlds

Worst of both worlds

Immune Response Corp. shares suffered a 40 percent shellacking last week, which we suppose could be attributed to inconclusive data from the Phase II/III trial of its HIV therapeutic vaccine. Or, equally simply, to the rout of investors who continue to march into the biotech tar pits

Read the full 518 word article

How to gain access

Continue reading with a
two-week free trial.